STING1 and ovarian serous adenocarcinoma: Specifically, in a syngeneic genetically engineered mouse model of high-grade serous ovarian cancer driven via concurrent loss of p53 and Brca1 and overexpression of c-Myc, PARP inhibitor olaparib induced activation of Stimulator of Interferon Genes (STING) pathway accompanied by increased expression of Interferon-beta, PD-L1 and CXCL104.